FB23-2 exerts therapeutic effects against T-ALL through the FTO/m6A/MYC axis.

ABSTRACT: T-cell acute lymphoblastic leukemia (T-ALL) is a pediatric hematological malignancy that presents significant challenges. RNA N6-methyladenosine (m6A) methylation is crucial in tumorigenesis, and the m6A demethylase FTO has emerging importance in cancers; however, its specific role in T-ALL pathogenesis remains incompletely understood. In vitro studies employed T-ALL cell lines treated with the FTO inhibitor FB23-2. Our findings indicate that FB23-2 may exert therapeutic effects against T-ALL primarily through the FTO/m6A/MYC axis.

ORGANISM(S): Homo sapiens

PROVIDER: GSE317759 | GEO | 2026/05/19

REPOSITORIES: GEO